Bill · H.R. 9774· House(119-HR-9774)
To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
- Introduced
- 7/20/2026
- Last activity
- 7/20/2026 — Referred to the House Committee on Energy and Commerce.
- Sponsored by
- Robert Latta
- Cosponsors
- - 0 - 1
- Introduced
- In Committee
What this bill would do
This bill seeks to amend the Federal Food, Drug, and Cosmetic Act to create a pathway for the expedited approval of priority nonprescription drugs. Under this proposal, the Secretary can designate certain drugs as "priority" if they meet specific criteria, such as being a new molecular entity or providing a novel nonprescription indication. Once designated, the Secretary will take various actions to facilitate and speed up the development and review process of these drugs. The bill also requires the establishment of a list of conditions that could benefit from these drugs. Finally, the authority granted by this bill is set to expire on September 30, 2032.
Yes· 3 of 7
Does this make health care easier to get in general?+5
The bill expedites the availability of new nonprescription drugs for various conditions, potentially increasing easier access to treatments.
Does this make it easier to run a small business?+3
The bill provides a streamlined regulatory pathway that can benefit drug sponsors developing new nonprescription treatments.
Does this make what the government does easier for the public to see?+3
The bill requires the Secretary to publish a list of conditions and submit a report to Congress regarding the program's implementation.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Faster Access to New Drugs: The bill allows the Secretary to take actions to "expedite the review of, an application or supplement to an application for such drug," which could lead to faster availability of new treatments (Section 506M(e)).
-
Meaningful Public Health Benefits: Priority designation can be granted to drugs intended for a "novel nonprescription indication that could provide a meaningful public health benefit" (Section 506M(d)(1)(A)).
-
Efficient Development Programs: The Secretary is directed to provide advice and communication to ensure development programs for gathering data are "as efficient as practicable" (Section 506M(e)(2)).
-
Streamlined Clinical Trials: The bill encourages making the design of nonclinical or clinical trials as efficient as possible, including the use of "real world evidence" (Section 506M(e)(5)).
Potential Negative Impacts for People
- Exclusion of Certain Drugs: Drugs that require a "risk evaluation and mitigation strategy" or are "controlled substance[s]" are not eligible for this expedited priority designation (Section 506M(d)(2)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Healthcare
- Improves Healthcare Access+5Increases Research Funding+2
- Demographic And Interest Groups
- Good For Low Income Households+2Good For Urban Residents+1
- Economy And Finance
- Improves Small Business Support+3
- Governance And Ideology
- Improves Government Transparency+3
- Education And Technology
- Increases Scientific Research Funding+2
- 7/20/2026
- Referred to the House Committee on Energy and Commerce.
- 1 Cosponsor added.
- Introduced in House
Greg LandsmanDemocrat · Ohio